Global Antisense & RNAi Therapeutics Market (2020 to 2030)

2021-04-13

基因疗法疫苗并购合作

Dublin, April 07, 2021 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market. The global antisense and RNAi therapeutics market reached a value of nearly $3,677.3 million in 2020, having increased at a compound annual growth rate (CAGR) of 38.2% since 2017. The market is expected to grow from $3,677.3 million in 2020 to $5,660.6 million in 2025 at a rate of 9.0%. The growth is mainly due to the growing demand for antisense and RNAi therapeutics due to COVID-19 which is expected to drive the demand for antisense and RNAi therapeutics. The market is expected to grow to $8,261.2 million in in 2030 at a CAGR of 7.9%. Reasons to Purchase Description:Where is the largest and fastest growing market for the antisense & RNAi therapeutics market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global antisense & RNAi therapeutics market opportunities and strategies to 2030 report answers all these questions and many more.The report covers the following chapters The antisense & RNAi therapeutics market is highly concentrated, with a small number of large players. The top ten competitors in the market made up to 95.74% of the total market in 2019. Major players in the market include Biogen Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Moderna, Inc. and others. The top opportunities in the antisense and RNAi therapeutics market segmented by technology will arise in the antisense RNA segment, which will gain $1,362.3 million of global annual sales by 2025. The top opportunities in the antisense and RNAi therapeutics market segmented by route of administration will arise in the intravenous injections segment, which will gain $962.6 million of global annual sales by 2025. The top opportunities in the antisense and RNAi therapeutics market segmented by indication will arise in the other indications segment, which will gain $ 1,056.1 million of global annual sales by 2025. The antisense and RNAi therapeutics' market size will gain the most in the USA at $737.1 million. Market-trend-based strategies for the antisense and RNAi therapeutics market includes focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, develop new and improved antisense and RNAi therapeutics, and collaborate with other companies for product innovation and to drive revenues. Player-adopted strategies in the antisense and RNAi therapeutics market include investing in expanding operations through innovative product launches, and in acquisitions and mergers to strengthen their service offerings.To take advantage of the opportunities, the publisher recommends the antisense & RNAi therapeutics to focus on research and development for RNAi therapeutics to treat orphan diseases, expand product portfolios through collaborations, offer skimmed pricing, expand in emerging markets, promote their drugs through physicians and NGOs, increase visibility through websites and target people suffering from various diseases. Key Topics Covered: 1. Antisense & RNAi Therapeutics Market Executive Summary 2. Table of Contents 3. List of Figures 4. List of Tables 5. Report Structure 6. Introduction 6.1. Segmentation by Geography 6.2. Segmentation by Technology 6.3. Segmentation by Route of Administration 6.4. Segmentation by Indication 7. Antisense & RNAi Therapeutics Market Characteristics 7.1. Market Definition 7.2. Segmentation by Technology 7.2.1. RNA Interference 7.2.2. Antisense RNA 7.3. Segmentation by Route of Administration 7.3.1. Intravenous Injections 7.3.2. Intra-Dermal Injections 7.3.3. Other Delivery Methods 7.4. Segmentation by Indication 7.4.1. Oncology 7.4.2. Cardiovascular Diseases 7.4.3. Respiratory Disorders 7.4.4. Neurological Disorders 7.4.5. Infectious Diseases 7.4.6. Other Diseases 8. Antisense & RNAi Therapeutics Market Trends and Strategies 8.1. Demand for RNAi Therapeutics in the Treatment of Orphan Diseases 8.2. Revised FDA Regulations to Facilitate Drug Development 8.3. Growing Demand for Nanoparticles for Drug Delivery 8.4. Strategic Collaborations and Partnerships 9. COVID-19 Impact on the Antisense & RNAi Therapeutics Market 9.1. Using Antisense and RNAi Therapeutics in COVID-19 Vaccines 9.2. How Antisense and RNAi Companies are Tackling the Virus 10. Global Antisense & RNAi Therapeutics Market Size and Growth 10.1. Market Size 10.2. Historic Market Growth, 2017 - 2020, Value ($ Million) 10.2.1. Drivers of the Market 2017-2020 10.2.2. Restraints on the Market 2017-2020 10.3. Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million) 10.3.1. Drivers of the Market 2020-2025 10.3.2. Restraints on the Market 2020-2025 11. Global Antisense & RNAi Therapeutics Market Segmentation 11.1. Global Antisense & RNAi Therapeutics Market, Segmentation by Technology11.2. Global Antisense & RNAi Therapeutics Market, Segmentation by Route of Administration11.3. Global Antisense & RNAi Therapeutics Market, Segmentation by Indication12. Antisense & RNAi Therapeutics Market, Regional and Country Analysis 12.1. Global Antisense & RNAi Therapeutics Market, by Region, Historic and Forecast, 2017 - 2020, 2025F, 2030F, Value ($ Million) 12.2. Global Antisense & RNAi Therapeutics Market, by Country, Historic and Forecast, 2017 - 2020, 2025F, 2030F, Value ($ Million) 13. Asia-Pacific Antisense & RNAi Therapeutics Market 14. Western Europe Antisense & RNAi Therapeutics Market 15. Eastern Europe Antisense & RNAi Therapeutics Market 16. North America Antisense & RNAi Therapeutics Market 17. South America Antisense & RNAi Therapeutics Market 18. Middle East Antisense & RNAi Therapeutics Market 19. Africa Antisense & RNAi Therapeutics Market 20. Global Antisense & RNAi Therapeutics Market Competitive Landscape 20.1. Company Profiles 20.2. Biogen Inc. 20.2.1. Company Overview 20.2.2. Products and Services 20.2.3. Business Strategy 20.2.4. Financial Overview 20.3. Ionis Pharmaceuticals, Inc. 20.3.1. Company Overview 20.3.2. Products and Services 20.3.3. Business Strategy 20.3.4. Financial Overview 20.4. Alnylam Pharmaceuticals, Inc. 20.4.1. Company Overview 20.4.2. Products and Services 20.4.3. Business Strategy 20.4.4. Financial Overview 20.5. Arrowhead Pharmaceuticals, Inc. 20.5.1. Company Overview 20.5.2. Products and Services 20.5.3. Business Strategy 20.5.4. Financial Overview 20.6. Moderna, Inc. 20.6.1. Company Overview 20.6.2. Products and Services 20.6.3. Business Strategy 20.6.4. Financial Overview 20.7. Sanofi S.A. 20.7.1. Company Overview 20.7.2. Products and Services 20.7.3. Business Strategy 20.7.4. Financial overview 20.8. Dicerna Pharmaceuticals, Inc. 20.8.1. Company Overview 20.8.2. Products and Services 20.8.3. Business Strategy 20.8.4. Financial overview 21. Key Mergers and Acquisitions in the Antisense & RNAi Therapeutics Market 21.1. Secarna Pharmaceuticals Acquired Lipigon Pharmaceuticals 21.2. Astellas Pharma Acquired Gene Therapy Firm Audentes 21.3. Novartis International AG Acquired the Medicines Company 21.4. NeuBase Therapeutics Merged with Ohr Pharmaceutical 21.5. Novartis Acquired AveXis 22. Antisense & RNAi Therapeutics Market Opportunities and Strategies 22.1. Global Antisense & RNAi Therapeutics Market in 2025 - Countries Offering most New Opportunities 22.2. Global Antisense & RNAi Therapeutics Market in 2025 - Segments Offering most New Opportunities 22.3. Global Antisense & RNAi Therapeutics Market in 2025 - Growth Strategies 22.3.1. Market Trend Based Strategies 22.3.2. Competitor Strategies 23. Antisense & RNAi Therapeutics Market, Conclusions and Recommendations 24. Appendix For more information about this report visit

机构